The tweet was deleted by the author.
But we saved everything 🙂.
Jonah Lupton describes MELI as one of the most successful publicly traded companies, pointing out its unique record of achieving at least 30 percent year-over-year growth for more than 30 consecutive quarters.
He also notes that MELI is currently down 37 percent from its July 2025 highs.
Lupton's assessment of MELI's sustained growth and current valuation aligns with his broader observations on market dynamics, such as the heightened volatility reflected by the spike in HIMS short interest. His perspective on sector innovation also extends to advancements in healthcare, notably highlighting TMDX's efforts to address viable kidney wastage through technology.